<DOC>
	<DOC>NCT01197469</DOC>
	<brief_summary>The investigators hypothesise that phosphodiesterase 5A inhibitors will improve exercise capacity in those with Chronic Obstructive Pulmonary Disease and secondary pulmonary hypertension.</brief_summary>
	<brief_title>Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>COPD Forced expiratory volume in 1 second (FEV1) &lt;80% (FEV1/FVC &lt;0.70) Right ventricular systolic pressure (RVSP) &gt; 30 mmHg or Pulmonary Acceleration time &lt;120 ms Pulmonary stenosis or echo left ventricular outflow tract obstruction Left ventricular ejection fraction &lt; 45% Patients taking nitrates, nicorandil or doxazosin. Drug contraindications: Systolic Blood Pressure &lt;90 mmHg recent stroke unstable angina past history of non arteritic anterior ischaemic optic neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Secondary Pulmonary Hypertension</keyword>
</DOC>